Successful Participation at ATTD 2025 in Amsterdam
At the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025), Professors Pieter Gillard, Carine de Beaufort, and Helen Murphy provided in-depth insights into how myLoop powered by CamAPS FX improves both clinical outcomes and quality of life for people with Type 1 Diabetes (T1D) and their caregivers. The discussion highlighted compelling real-world evidence, including improved HbA1c levels, increased time in range, and positive user experiences, reinforcing myLoop’s impact on personalised diabetes care at every life stage.
Simplifying Diabetes Management for All People with T1D; Prof. Pieter Gillard, UZ Leuven, Belgium
Prof. Gillard discussed how myLoop simplifies diabetes management through its hybrid closed-loop technology and adaptive algorithm for a wide range of people living with T1D. This technology automatically adjusts insulin delivery based on real-time glucose readings, significantly improving time-in-range (TIR) for people with T1D. It enhances their quality of life by reducing the burden of constant monitoring and supports exercise management by allowing users to lower the bolus dose and utilize the Ease-off function.
Key Insights:
Reduced manual interventions: By automating basal insulin dosing, myLoop reduces the need for manual adjustments, offering a simpler and more adaptable approach to diabetes management.
Key features of myLoop: Clinical data demonstrated significant improvements in TIR, Time Below Range (TBR), and HbA1c for users. Key features such as the CamAPS FX app, easy bolusing, many more options for personal glucose target, approved use in pregnancy and very young children, and compatibility with both Dexcom G6 and FreeStyle Libre sensors distinguishes myLoop from other systems in the market.
myLoop’s adaptability to varying activity levels: myLoop powered by CamAPS FX seamlessly adjusts basal delivery fluctuations throughout the day, supports mealtime adjustments with Simplified Meal Announcement, and reduces stress, thereby leading to better glucose regulation. This minimises the risk of both hyperglycaemia and hypoglycaemia, making diabetes management easier and more effective for people with T1D even during exercise.
Impact of Hybrid Closed-Loop on Quality of Life of Carers of the Very Young with T1D; Prof. Carine de Beaufort, Centre Hospitalier de Luxembourg, Luxembourg
Managing T1D in very young children is a major challenge, not only for caregivers who have to constantly monitor glucose levels and insulin administration based on children's unpredictable eating and activity patterns, but also because it has a huge psychological impact on them.
Prof. Carine de Beaufort highlighted how myLoop has significantly reduced the burden on parents and caregivers of young children with T1D. She presented data over an 18-month period where myLoop demonstrated significant improvements in glycaemic management in children aged ≥1 years compared to SAP therapy, without increasing the risk of hypoglycaemia. Notably, 70% of these children achieved an HbA1c of less than 7%, thereby reducing the fear of hypoglycaemia.1
Key Insights:
Improved sleep quality: myLoop’s automatic insulin adjustments at night result in fewer nighttime interventions, allowing caregivers to get more rest.
Reduced stress and anxiety: Caregivers feel more confident and less anxious due to myLoop’s enhanced efficacy, particularly through Boost and Ease-off. The automation of insulin adjustments eliminates the need for frequent manual interventions.2
Remote monitoring: myLoop enables parents to “be present while absent” (Prof. Carine de Beaufort), facilitating oversight and collaboration with other caregivers.
Healthy glucose range: Automated insulin adjustments help maintain a healthy glucose range, reducing both hyperglycaemic and hypoglycaemic events. This leads to improved sleep, mood, and concentration for the child, while also reducing overall distress.
A call for early adoption: de Beaufort advocates for making myLoop available to all children with T1D immediately upon diagnosis.
Using CamAPS FX for Advanced Adaptive Automated Insulin Dosing Before, During, and After T1D Pregnancy; Prof. Helen Murphy, University of East Anglia, Norwich, UK
Maintaining optimal glucose control during pregnancy is crucial for both maternal and fetal health. Prof. Helen Murphy presented evidence demonstrating that CamAPS FX provides adaptive insulin delivery before, during, and after pregnancy, leading to significantly better outcomes. Notably, Time in Range in pregnancy (TIRp) improved by 10.5 percentage points within just one week of myLoop initiation, with benefits extending across gestation and the full 24-hour cycle.3
She emphasized that women can safely transition to myLoop at any stage of pregnancy and experience immediate benefits, including 3.7 kg less gestational weight gain, a lower risk of gestational hypertension, and reduced rates of large-for-gestational-age (LGA) births and NICU admissions.3
Furthermore, health economics evaluations indicate that myLoop powered by CamAPS FX has the potential to generate significant cost savings by reducing pregnancy-related complications, such as LGA births and NICU admissions, particularly when adopted as early as possible in pregnancy.
Key Insights:
Improved Glucose Management: Women using CamAPS FX during pregnancy achieve improved Time in Range (TIR) and lower HbA1c levels compared to the standard care group.3
Reduced Risk of Complications: myLoop’s adaptability ensures real-time insulin adjustments to help prevent both hyperglycaemia and hypoglycaemia, lowering the risk of pregnancy complications.3
Postpartum Support: CamAPS FX ensures smoother glucose management after childbirth, reducing the effort required for diabetes management and minimising postnatal complications.4
Comprehensive Diabetes Care: By providing tight glucose management before, during, and after pregnancy, CamAPS FX enhances maternal and fetal health while simplifying diabetes management during pregnancy.3,4
Advocacy for Early Adoption: Prof. Murphy recommends that it is best to offer the myLoop to all women with T1D before, during, and after pregnancy as early as possible.